ArticleJournal of neuro-oncology2018
Solitary-fibrous tumor/hemangiopericytoma of the central nervous system: a population-based study.
Article in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 4 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- A systematic review and meta-analysis on the efficacy of postoperative radiotherapy after gross total resection of intracranial solitary fibrous tumors.Scientific reports · 2025Pooled it
- Postoperative stereotactic radiosurgery for intracranial solitary fibrous tumors: systematic review and pooled quantitative analysis.Journal of neuro-oncology · 2023Pooled it
- Impact of extent of resection and postoperative radiotherapy on survival outcomes in intracranial solitary fibrous tumors: a systematic review and meta-analysis.Neurosurgical review · 2023Pooled it
- Skull base hemangiopericytomas.Acta neurologica Belgica · 2022Pooled it
- Giant calvarial solitary fibrous tumor with intracranial and extracranial extension in an elderly patient: imaging and surgical considerations.Radiology case reports · 2026Article
- Carbon-Ion Radiation Therapy for Unresectable Solitary Fibrous Tumor of the Intermediate Category: A Nationwide Multi-institutional Observational Study by the Japan Carbon-Ion Radiation Oncology Study Group.Advances in radiation oncology · 2026Article
- Clinical presentation and survival outcome of solitary fibrous tumors of the central nervous system: a single center study.BMC neurology · 2026Article
- Multimodal MRI-based nomogram integrating clinical-radiological, radiomic, and habitat features to discriminate solitary fibrous tumors from atypical meningiomas.Scientific reports · 2026Article
- Systemic Therapy for Solitary Fibrous Tumor.Current treatment options in oncology · 2026Review
- Long-term control of grade 3 intracranial solitary fibrous tumor achieved with pazopanib and stereotactic radiotherapy: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- Survival and prognostic factors of anaplastic hemangiopericytoma/solitary fibrous tumor grade III.Acta neurochirurgica · 2026Article
- Cytologic and Histologic Findings of Extrapleural Solitary Fibrous Tumor: Report of Two Cases.Diagnostic cytopathology · 2026Article
- Advances in the multimodal management of central nervous system solitary fibrous tumors.Frontiers in oncology · 2026Review
- Pediatric Spinal Solitary Fibrous Tumor: A Systematic Review of a Rare Condition.Children (Basel, Switzerland) · 2025Review
- Intraventricular metastasis with malignant progression of an intraspinal solitary fibrous tumor: a case report and review of the literature.Journal of medical case reports · 2025Review
- WHO Grade II or III Solitary Fibrous Tumors (Hemangiopericytomas) of the Spine: Two Case Reports with a Comprehensive Review of the Literature.Journal of clinical medicine · 2025Article
- Molecular landscape, subtypes, and therapeutic vulnerabilities of central nervous system solitary fibrous tumors.Nature communications · 2025Article
- The association between WHO grading and the long-term outcomes and radiotherapy efficacy of intracranial solitary fibrous tumors.Acta neuropathologica communications · 2025Article
- Meningeal malignant solitary fibrous tumor with multiple recurrence, extracranial extension, cervical lymph node metastases: case report and review of the literature.Discover oncology · 2025Article
- Solitary fibrous tumor in the pineal region: A series of 5 cases and literature review.Journal of neuropathology and experimental neurology · 2025Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The World Health Organization (WHO) classification of tumors of the central nervous system (CNS) was recently updated, restructuring solitary fibrous tumor (SFT) and hemangiopericytoma (HPC) into one combined entity. This is the first population-based study to examine outcomes of SFT/HPC based on the new WHO guidelines. The Surveillance, Epidemiology, and End Results (SEER) database (1998-2013) was queried to examine age-adjusted incidence and prognostic factors associated with overall survival in 416 surgically resected cases. Age-adjusted incidence was calculated to be 3.77 per 10,000,000 and was rising. Median survival was 155 months, with 5- and 10-year survival rates of 78 and 61%, respectively. Younger age, Asian/Pacific Islander versus white race, benign histology, tumor location, gross-total resection (GTR), and GTR plus radiation (RT) versus subtotal resection were significantly associated with survival. In multivariable analysis, older age (HR = 1.038, p < 0.0001), infratentorial location (HR = 2.019, p = 0.038), GTR (HR = 0.313, p = 0.041), and GTR + RT (HR = 0.215, p = 0.008) were independent prognostic factors. In the HPC and borderline/malignant subgroups, GTR + RT was associated with significantly increased survival compared with GTR alone (HR = 0.537, p = 0.039 and HR = 0.525, p = 0.038). After eliminating patients that died within 3 months of diagnosis, GTR + RT was still associated with an incremental increase in survival (HR = 0.238, p = 0.031) over GTR alone (HR = 0.280, p = 0.054). GTR + RT may be optimal in the management CNS HPC and SFT/HPC tumors with borderline/malignant features. This study, in combination with existing literature, warrants further investigation of adjuvant radiation through a prospective clinical trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.